Library / Weight and metabolic

Mazdutide

Also known as IBI362, LY3305677

Human trials

Dual GLP-1 and glucagon receptor agonist peptide. Phase 3 trials in Chinese adults with obesity and with type 2 diabetes have been published.

Not an approved medicine. Mazdutide is not an approved medicine for this use in Australia or the United States. This page summarises published research for information only. It is not a recommendation to use Mazdutide, and VialOwl does not sell or supply it.

Background

Mazdutide (LY3305677, IBI362) was created by Eli Lilly and is developed in China by Innovent Biologics. It is modelled on oxyntomodulin, a natural gut hormone. In June 2025 it was approved in China for long term weight management, and in September 2025 for type 2 diabetes.

How it is thought to work

Mazdutide activates both the GLP-1 receptor, which reduces appetite and improves blood sugar control, and the glucagon receptor, which is thought to increase energy use and liver fat burning. It is injected once a week.

What is claimed, and the evidence

Claim	Evidence	Notes
Weight loss in adults with obesity or overweight	Human trials	Phase 3 GLORY-1 trial (610 Chinese adults): about 11 to 14 per cent average weight loss at 48 weeks versus about 0 per cent with placebo. Approved in China but not by the TGA, FDA or EMA.
Blood sugar control in type 2 diabetes	Human trials	Phase 3 trial of 320 Chinese adults: HbA1c fell 1.6 to 2.2 percentage points at 24 weeks versus 0.1 with placebo.
Liver fat reduction, sleep apnoea, alcohol use disorder	Small human studies	Under clinical evaluation; no approvals for these uses.

Side effects

Effect	How often	Notes
Diarrhoea	Common	Among the most common adverse events in the type 2 diabetes phase 3 trial.
Nausea and vomiting	Common	Gastrointestinal events were the most frequent, mostly mild to moderate.
Decreased appetite	Common	Reported commonly in the type 2 diabetes trial.
Stopping treatment because of side effects	Uncommon	0.5 to 1.5 per cent in GLORY-1, similar to placebo.
Rare serious effects seen with this drug class (pancreatitis, gallbladder disease) Serious	Frequency unknown	Not reported in the abstracts reviewed; longer and larger trials are needed to define rare risks.

Warnings

Trials so far have been mainly in Chinese adults; it is not approved in Australia, the US or Europe.
Unapproved products are not assessed by the TGA for quality, safety or efficacy and may be contaminated, non-sterile, underdosed, overdosed or contain a different substance altogether.

Regulatory status

Australia: Not included on the ARTG (unapproved). Not specifically listed in the Poisons Standard (June 2026).
United States: Not FDA approved. Approved in China (NMPA) for obesity and weight management (Not verified from NMPA directly).

Sources

Also in Weight and metabolic

From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use Mazdutide.